TYME - TYME STOCK NEWS

Tyme Technologies, Inc. (Nasdaq:TYME) conducted a strategic review under new CEO Richie Cunningham, leading to a diversified clinical pipeline and enhanced management. The company announced the OASIS breast cancer trial with Georgetown University, evaluating SM-88 in treating HR+/HER2- metastatic breast cancer. Additionally, TYME will focus on the Precision Promise pancreatic cancer trial, ceasing enrollment in the TYME-88-Panc trial due to slower-than-expected progress. As of Q4 2021, TYME had $107.5 million in cash and anticipated a cash burn rate of $6.0 to $8.0 million per quarter for FY2022.

TYME Technologies, Inc. (Nasdaq: TYME) announced a conference call and live video webcast on June 10, 2021, at 5:00 PM ET to discuss its fiscal year 2021 financial results and provide a business update. The session will include insights from the CEO, Richie Cunningham, on the company's strategic review, focusing on its drug development pipeline and efficiency of capital expenditures. Participants can join by phone or via a webcast, and a Q&A session will follow. Questions for management must be submitted by June 8, 2021. For more details, visit tymeinc.com.

TYME Technologies announces the appointment of Frank L. Porfido as Chief Financial Officer, effective after filing its annual report. Porfido, with over 25 years in biotech finance, previously held significant roles at Novartis and recently served as Vice President of Finance at UroGen Pharma. CEO Richie Cunningham emphasized the importance of this leadership change as the company aims to finalize its strategic review of pipeline programs. Porfido's expertise is expected to enhance TYME's strategic direction during a transformative year for the company.

TYME Technologies, Inc. (Nasdaq: TYME) announced that an abstract on its investigational therapy SM-88 will be published at the virtual ASCO Annual Meeting from June 4-8, 2021. The abstract, titled Phase II Study of SM-88 in Ewing’s and Other Sarcomas, focuses on promising results across 15 cancers with minimal serious adverse events noted. SM-88 is designed to disrupt cancer cell metabolism, potentially leading to cell death. It remains an investigational therapy and is not yet FDA approved.

Tyme Technologies, Inc. (NASDAQ: TYME) has appointed Jan M Van Tornout, MD, MSc, as acting Chief Medical Officer, effective April 1, 2021. He replaces Dr. Giuseppe Del Priore and will lead medical and preclinical programs. Dr. Van Tornout brings over 25 years of experience in drug development across multiple organizations. TYME aims to leverage his expertise in progressing its pipeline, focusing on cancer metabolism-based therapies. The company is optimistic that his leadership will enhance submission quality to the FDA and improve outcomes for patients with unmet medical needs.

Tyme Technologies, Inc. (NASDAQ: TYME) closed a registered direct offering of 40 million shares at $2.50 per share, generating gross proceeds of $100 million. H.C. Wainwright & Co. acted as the exclusive placement agent. The proceeds will fund clinical and preclinical asset development, general corporate purposes, working capital, and potential acquisitions, although no current agreements exist. The shares were offered under a shelf registration statement, with filings available on the SEC's website.

Tyme Technologies, Inc. (NASDAQ: TYME) reported its third quarter fiscal 2021 results, citing a cash balance of approximately $13.5 million, down from $19.4 million. The operational cash burn rate decreased to $5.9 million, below estimates. CEO Richie Cunningham emphasized ongoing strategic reviews. Key upcoming events include further enrollment in ongoing clinical trials and anticipated data readouts in 2021. The company continued to expand its patent portfolio, now nearly 200 patents, including recent claims for TYME-19 to treat COVID-19.

Tyme Technologies (NASDAQ: TYME) announced a registered direct offering of 40 million shares at $2.50 per share, aiming to raise $100 million. The offering is set to close around February 8, 2021, pending customary conditions. Proceeds will support the development of clinical and preclinical assets, corporate purposes, and potential investments in complementary businesses, although no current acquisitions are planned. H.C. Wainwright & Co. is the placement agent for this offering, conducted under SEC regulations.

Tyme Technologies (NASDAQ: TYME) reported the granting of additional patent claims by the U.S. Patent Office for its metabolomic technology platform, specifically related to treating COVID-19. The compound, TYME-19, acts on cellular metabolism rather than targeting the virus directly, potentially making it effective against variants. Preclinical studies indicate TYME-19 inhibits COVID-19 replication without damaging healthy cells. The company plans to initiate clinical trials to further assess its safety and efficacy.